| scholarly article | Q13442814 |
| P50 | author | Zachary T Bloomgarden | Q65055010 |
| P2860 | cites work | Obesity and Risk for Chronic Renal Failure | Q22241459 |
| Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency | Q79485416 | ||
| Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial | Q80688403 | ||
| Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q84696837 | ||
| Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol | Q28318336 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Obesity-related glomerulopathy: an emerging epidemic | Q34190647 | ||
| Glomerular number and size in autopsy kidneys: the relationship to birth weight | Q34533810 | ||
| Telmisartan to prevent recurrent stroke and cardiovascular events | Q34596294 | ||
| Plasma 25-hydroxyvitamin D levels and risk of incident hypertension | Q34610247 | ||
| Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys | Q35752310 | ||
| Pathophysiology of hypertensive renal damage: implications for therapy | Q35903433 | ||
| Obesity, proteinuria and progression of renal failure | Q36568186 | ||
| Obesity and renal hemodynamics | Q36575280 | ||
| Improving Diabetes Care in Practice: findings from the TRANSLATE trial. | Q36975614 | ||
| Adverse renal consequences of obesity | Q37072213 | ||
| Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria | Q37364926 | ||
| Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis | Q37400779 | ||
| Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease | Q38388348 | ||
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | Q39669015 | ||
| The hyperfiltration theory: a paradigm shift in nephrology | Q41066752 | ||
| Ultraviolet light may contribute to geographic and racial blood pressure differences | Q41566569 | ||
| Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial | Q42542786 | ||
| Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure | Q43266277 | ||
| Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. | Q43266787 | ||
| Veterans Affairs diabetes trial--corrections | Q43281794 | ||
| Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women | Q43571607 | ||
| Dipstick proteinuria: can it guide hypertension management? | Q44015503 | ||
| Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 | ||
| The effects of weight loss on renal function in patients with severe obesity | Q44449830 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis | Q46610834 | ||
| Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 | ||
| Antiproteinuric effect of oral paricalcitol in chronic kidney disease | Q46826570 | ||
| Body mass index and risk for end-stage renal disease | Q46876497 | ||
| Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. | Q47312548 | ||
| A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. | Q51486727 | ||
| Structure-stabilizing forces in the glomerular tuft. | Q55065103 | ||
| Dual inhibition of the renin system by aliskiren and valsartan | Q57085467 | ||
| Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial | Q61455820 | ||
| Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR | Q73834111 | ||
| Association of calcitriol and blood pressure in normotensive men | Q73879508 | ||
| Class differences in the effects of calcium channel blockers in the rat remnant kidney model | Q77410518 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diabetic nephropathy | Q1129105 |
| P304 | page(s) | e30-5 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Blood pressure and diabetic nephropathy | |
| P478 | volume | 33 |
Search more.